Rady Children's Hospital Diagnoses critically ill children using artificial intelligence

25 April 2019 - San Diego, Leuven - Researchers at the Rady Children's Hospital in San Diego have for the first time used artificial intelligence to diagnose children with rare genetic disorders in record time. The results are published today in the leading journal Science Translational Medicine.

The Rady Children’s Hospital used Moon, software developed by the Leuven-based company Diploid. Moon is the first software worldwide to use AI for the diagnosis of rare diseases.

This new method accelerates the diagnosis of seriously ill children in intensive care and opens the door to the use of genome sequencing as a first-line diagnostic test for babies with unknown disorders. An estimated 4 percent of newborns are affected by genetic diseases, which are the leading cause of death in infants. Rare genetic diseases also account for around 15 percent of admissions to children's hospitals.

“Some people call this artificial intelligence, we call it augmented intelligence,” said Stephen Kingsmore, MD, DSc, President and CEO of RCIGM. “Patient care will always begin and end with the doctor. By harnessing the power of technology, we can quickly and accurately determine the root cause of genetic diseases. We rapidly provide this critical information to intensive care physicians so they can focus on personalizing care for babies who are struggling to survive.”

By reducing the need for labor-intensive manual analysis of genomic data, the automated approach saved a considerable amount of time. In February 2018, the same team set the world record for the fastest diagnosis by sequencing the entire genome.

"Saving the lives of very sick newborn babies by using AI in genome analysis is truly groundbreaking work for the Rady team," said Eric Topol, MD, professor of molecular medicine at Scripps Research.

The Rady Children's Hospital has optimized various time-saving technologies and integrated them into a rapid process to screen the entire genetic composition of a child for thousands of genetic abnormalities, based on a blood sample.

A crucial element in this process is the Moon software developed by Diploid in Leuven. The platform automates the interpretation of the genetic data via AI to automatically filter and classify pathogenic mutations. Integration of the patient's symptoms, based on analysis of the medical literature, is one of the main pillars of this automated interpretation. With Moon, it takes only five minutes to find the causal mutation amidst the 4.5 million mutations in a fully human genome.

The study emphasizes that these automated diagnoses corresponded to manual interpretation by experts. The Leuven Moon software achieved 99 percent precision in 95 children with 97 genetic disorders.

"This publication of the Rady Children's Hospital is an absolute first," said Peter Schols, CEO of Diploid. “For the first time in history, an algorithm matches the precision of a geneticist in diagnosing rare diseases. Of course there is always a manual check by a geneticist and the treating physician, but as the research results indicate, our Moon software achieved 99% precision in finding the genetic cause, which is unseen in our sector. We are delighted with these results. The Rady Children's Hospital is one of the very best children's hospitals in the US and even worldwide, and it is an honor that they have chosen our software.”

Researchers concluded that this highly automated approach allows the use of genome analysis in intensive care units, giving seriously ill children the rapid and accurate medical care they require.

Increased process automation removes a barrier to scaling up clinical use of genome sequencing by reducing the need for time-consuming manual analysis and interpretation of data by scarce clinical geneticists.

“Using machine-learning platforms doesn’t replace human experts. Instead it augments their capabilities,” said Michelle Clark, PhD, statistical scientist at RCIGM and the first author of the study. “By informing timely targeted treatments, rapid genome sequencing can improve the outcomes of seriously ill children with genetic diseases.”

Share:


Genomenon, Diploid Partner to Accelerate Rare Disease Detection

ANN ARBOR, MI and LEUVEN, BELGIUM; February 19, 2019​ -- ​Diploid​, leading AI-based software provider for rare disease diagnostics, and ​Genomenon®​ ​, the genomic search company, announced today that they have entered into a partnership to improve genome interpretation for rare disease diagnostics.

With its ​Moon software​, Diploid provides the most efficient workflow for rare disease diagnostics. Moon allows its users to go from VCF to causal variant in just minutes thanks to advanced machine learning and deep phenotype integration. As a result, the software was selected by Dr. Stephen Kingsmore at Rady Children's Hospital to establish a new world record for fastest genome interpretation in the NICU (​Read the Rady story​).

"Moon returns a very short list of variants that might be relevant for the patient's phenotype: typically about 4-8 variants for exome or whole genome data" says Peter Schols, Diploid's founder and CEO. "This breakthrough saves clinical laboratory scientists a lot of time compared to manually filtering and curating hundreds or even thousands of variants."

Cyrielle Kint, Diploid's CSO, adds: "We wanted to make the process of evaluating the handful of remaining variants reported by Moon even more efficient, and that's why we are integrating with Genomenon's Mastermind®​ ​, the clear leader in genomic search engines." Genomenon’s ​Mastermind Genomic Search Engine​ filters and prioritizes millions of genomic articles to find the most useful and meaningful citations, saving scientists hours of literature curation per case and improving the chances of finding key genetic information that could be critical for a patient’s diagnosis.

The new integration allows users to see which candidate variants are mentioned in relevant publications and gives users direct access to Mastermind from Moon's user interface. "We're thrilled to partner with Diploid to reduce the time needed to identify the cause of genetic illness that can be life-threatening," said Mike Klein, CEO of Genomenon. "With integrated Mastermind search results, Moon users get an immediate view of the literature supporting each variant, and can speed their genomic interpretation for rare diseases.”

Both companies will be demonstrating the integration at the ACMG Annual Clinical Genomics Meeting conference taking place in Seattle, Washington April 2-6, 2019.

About Genomenon

Genomenon powers evidence-based genomics for faster; more comprehensive diagnosis and treatment decisions. Their flagship product, the​ ​Mastermind Genomic Search Engine​ provides immediate insight into the published genomic research for every disease, gene, and variant found in the literature. Used by hundreds of diagnostic labs around the world, Mastermind accelerates genomic interpretation by providing unique insight into genomic relationships found in the full text of millions of scientific articles. Pharmaceutical researchers license the Mastermind database for a comprehensive genomic landscape associated with any given disease – to identify and prioritize genomic biomarkers for drug discovery and clinical trial targets. For more information, visit​ ​www.genomenon.com​.

About Diploid

Diploid is on a mission to provide clinical labs, hospitals and nation-wide sequencing programs with the tools to diagnose every rare disease patient. Its Moon platform is the first software worldwide to use artificial intelligence for rare disease diagnostics. Thanks to its use of advanced machine learning and deep phenotype integration, Moon is now widely recognised as the fastest genome interpretation solution, going from whole genome VCF to diagnosis in minutes. In addition, Moon's autopilot feature enables unsupervised reanalysis of negative cases, making continuous genome interpretation a reality. Learn more at ​www.diploid.com/moon​.

https://www.genomenon.com/wp-content/uploads/2019/02/PR-Diploid-Genomenon.pdf

Share:


Join us at ASHG 2018 in San Diego

We'll be at the ASHG meeting in sunny San Diego. This year, Moon will be at the epicentre of the entire show floor: you can find us at booth 928, right across the ASHG Central. As promised, we'll be introducing structural variant interpretation alongside a slew of other updates and enhancements. Don't miss this opportunity to be among the first to learn how to diagnose even more patients with Moon.

Share:


Meet the Moon team at NVHG

Diploid will be sponsoring the Dutch Society of Human Genetics (NVHG) meeting taking place early next week in Papendal, The Netherlands. Feel free to visit our booth for a chat about variant interpretation, a Moon demo, or just to sample a Belgian chocolate.

Share:


Moon wins Best of Show award at Bio-IT World

We're really proud to announce that our Moon software has just received a 'Best of Show' award at Bio-IT World in Boston.

Share:


Moon helps Rady Children's Hospital in San Diego to establish new world record

Dr. Stephen Kingsmore and his team at Rady Children’s Institute for Genomic medicine just proved it’s possible to diagnose a rare disease patient based on whole genome sequencing in just 19.5 hours. Our Moon software has been used to provide clinical interpretation of the WGS data in just 4 minutes. Read the full story

Share:


Experience Moon at the Festival of Genomics


Diploid is delighted to be attending the Festival of Genomics in London, January 30 – 31. Come by our booth LP21 to witness how Moon diagnoses a rare disease patient in just two minutes.

Share: